Skip to main content

Advertisement

SpringerLink
Log in

HCC: Transarterial Therapies—What the Interventional Radiologist Can Offer

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

With the increasing incidence of hepatocellular carcinoma (HCC) and its high mortality rates, effective treatment options are of urgent need, preferably in a multidisciplinary setting. In the management of those patients, interventional radiologists play a key role. In this article, we reviewed the current literature for regional, intraarterial treatment strategies of advanced-stage HCC including conventional transarterial chemoembolization, transarterial embolization, transarterial embolization with drug-eluting beads, and selective internal radiation therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol. 2009;6:159–169.

    Article  PubMed  Google Scholar 

  2. Ganne-Carrié N, Chaffaut C, Bourcier V, et al. Estimate of hepatocellular carcinoma’s incidence in patients with alcoholic cirrhosis. J Hepatol. 2018;69:1274–1283.

    Article  PubMed  Google Scholar 

  3. Streba LA, Vere CC, Rogoveanu I, Streba CT. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol. 2015;21:4103–4110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kanda T, Matsuoka S, Yamazaki M, et al. Apoptosis and non-alcoholic fatty liver diseases. World J Gastroenterol. 2018;24:2661–2672.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127.

    Article  CAS  PubMed  Google Scholar 

  6. Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol. 2015;13:2140–2151.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Thomas MB, Jaffe D, Choti MM, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute clinical trials planning meeting. J Clin Oncol. 2010;28:3994–4005.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Rougier P, Mitry E, Barbare JC, Taieb J. Hepatocellular carcinoma (HCC): an update. Semin Oncol. 2007;34:S12–S20.

    Article  CAS  PubMed  Google Scholar 

  9. Lencioni R. Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies. Oncology. 2010;78:107–112.

    Article  PubMed  Google Scholar 

  10. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255.

    Article  PubMed  Google Scholar 

  11. Pesapane F, Nezami N, Patella F, et al. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58.

    Article  CAS  PubMed  Google Scholar 

  12. Molvar C, Lewandowski RJ. Intra-arterial therapies for liver masses: data distilled. Radiol Clin North Am. 2015;53:973–984.

    Article  PubMed  Google Scholar 

  13. Geschwind JF, Kudo M, Marrero JA, et al. TACE treatment in patients with sorafenibtreated unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON. Radiology. 2016;8:150667.

    Google Scholar 

  14. Trevisani F, Golfieri R. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: Where are we now? Hepatology. 2016;64:23–25.

    Article  PubMed  Google Scholar 

  15. European Association for the Study of the Liver1; European Organisation for Research and Treatment of Cancer. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.

    Article  Google Scholar 

  16. Ramsey DE, Kernagis LY, Soulen MC, et al. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2002;13:S211–S221.

    Article  PubMed  Google Scholar 

  17. Ahrar K, Gupta S. Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes. Surg Oncol Clin N Am. 2003;12:105–126.

    Article  PubMed  Google Scholar 

  18. Massmann A, Rodt T, Marquardt S, et al. Transarterial chemoembolization (TACE) for colorectal liver metastases–current status and critical review. Langenbecks Arch Surg. 2015;400:641–659.

    Article  PubMed  Google Scholar 

  19. Gruber-Rouh T, Naguib NN, Eichler K, et al. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period. Int J Cancer. 2014;134:1225–1231.

    Article  CAS  PubMed  Google Scholar 

  20. Chang J, Charalel R, Noda C, et al. Liver-dominant breast cancer metastasis: a comparative outcomes study of chemoembolization versus radioembolization. Anticancer Res. 2018;38:3063–3068.

    PubMed  Google Scholar 

  21. Wang M, Zhang J, Ji S, Shao G, et al. Transarterial chemoembolisation for breast cancer with liver metastasis: a systematic review. Breast. 2017;36:25–30.

    Article  PubMed  Google Scholar 

  22. Alexander ES, Soulen MC. Liver metastases from noncolorectal malignancies (neuroendocrine tumor, sarcoma, melanoma, breast). Cancer J. 2016;22:381–386.

    Article  CAS  PubMed  Google Scholar 

  23. Topaloglu S, Ozturk MH. Chemoembolization for neuroendocrine liver metastasis. Hepatogastroenterology. 2014;61:398–404.

    PubMed  Google Scholar 

  24. Grozinsky-Glasberg S, Kaltsas G, et al. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice. Endocrine. 2018;60:499–509.

    Article  CAS  PubMed  Google Scholar 

  25. Chen T, Chu ZH, Liu JP, et al. Application of adenosine triphosphate tumor chemosensitive assay system to individual chemotherapy for hepatocellular carcinoma. Aizheng. 2005;24:1018–1022. (Abstract).

    PubMed  Google Scholar 

  26. Wu J, Song L, Zhao DY, Guo B, Liu J. Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. World J Gastroenterol. 2014;20:10960–10968.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Gruber-Rouh T, Marko C, Thalhammer A, et al. Current strategies in interventional oncology of colorectal liver metastases. Br J Radiol. 2016;26:20151060.

    Article  Google Scholar 

  28. Schicho A, Hellerbrand C, Krüger K, et al. Impact of different embolic agents for transarterial chemoembolization (TACE) procedures on systemic vascular endothelial growth factor (VEGF) levels. J Clin Transl Hepatol. 2016;4:288–292.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the managementof intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37:212–220.

    Article  PubMed  Google Scholar 

  30. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–442.

    Article  CAS  PubMed  Google Scholar 

  31. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlledtrial. Lancet. 2002;359:1734–1739.

    Article  Google Scholar 

  32. Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma:meta-analysis of randomized controlled trials. Radiology. 2002;224:47–54.

    Article  PubMed  Google Scholar 

  33. Vande Lune P, Abdel Aal AK, Klimkowski S, et al. Hepatocellular carcinoma: diagnosis, treatment algorithms, and imaging appearance after transarterial chemoembolization. J Clin Transl Hepatol. 2018;6:175–188.

    PubMed  PubMed Central  Google Scholar 

  34. Takeba Y, Kumai T, Matsumoto N, et al. Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis. J Pharmacol Sci. 2007;104:232–242.

    Article  CAS  PubMed  Google Scholar 

  35. Maluccio M, Covey AM, Gandhi R, et al. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J Vasc Interv Radiol. 2005;16:955–961.

    Article  PubMed  Google Scholar 

  36. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474–481.

    Article  CAS  PubMed  Google Scholar 

  37. Poon RT, Tso WK, Pang RW, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol. 2007;5:1100–1108.

    Article  CAS  PubMed  Google Scholar 

  38. Nam HC, Jang B, Song MJ. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma. World J Gastroenterol. 2016;22:8853–8861.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Lencioni R, de Baere T, Burrel M, et al. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. 2012;35:980–985.

    Article  PubMed  Google Scholar 

  40. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41–52.

    Article  PubMed  Google Scholar 

  41. Malagari K. Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead. Expert Rev Anticancer Ther. 2008;8:1643–1650.

    Article  CAS  PubMed  Google Scholar 

  42. Han S, Zhang X, Zou L, et al. Does drugeluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A metaanalysis. PLoS One. 2014;9:e102686.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Molvar C, Lewandowski RJ. Intra-arterial therapies for liver masses: data distilled. Radiol Clin North Am. 2015;53:973–984.

    Article  PubMed  Google Scholar 

  44. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762–773.

    Article  CAS  PubMed  Google Scholar 

  45. Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151:1155–1163.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Dezarn WA, Cessna JT, DeWerd LA, et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2011;38:4824–4845.

    Article  PubMed  Google Scholar 

  47. Aubé C, Bouvier A, Lebigot J, et al. Radiological treatment of HCC: interventional radiology at the heart of management. Diagn Interv Imaging. 2015;96:625–636.

    Article  PubMed  Google Scholar 

  48. Vente MA, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol. 2009;19:951–959.

    Article  CAS  PubMed  Google Scholar 

  49. Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32:1387–1395.

    CAS  PubMed  Google Scholar 

  50. Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57:1826–1837.

    Article  CAS  PubMed  Google Scholar 

  51. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497–507.

    Article  PubMed  Google Scholar 

  52. Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol. 2012;56:464–473.

    Article  PubMed  Google Scholar 

  53. Golfieri R, Bilbao JI, Carpanese L, et al. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol. 2013;59:753–761.

    Article  PubMed  Google Scholar 

  54. Hatanaka T, Arai H, Shibasaki M, et al. Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon-occluded transcatheter arterial chemoembolization: a retrospective cohort study. Hepatol Res. 2018;48:165–175.

    Article  CAS  PubMed  Google Scholar 

  55. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–1171.

    Article  CAS  Google Scholar 

  56. Gruber-Rouh T, Kamal A, Eichler K, et al. Transarterial chemoembolization (TACE) using mitomycin with or without irinotecan for hepatocellular carcinoma in european patients. Oncol Res Treat. 2018;41:438–442.

    Article  CAS  PubMed  Google Scholar 

  57. Yamakado K, Miyayama S, Hirota S, et al. Hepatic arterial embolization for unresectable hepatocellular carcinomas: Do technical factors affect prognosis? Jpn J Radiol. 2012;30:560–566.

    Article  PubMed  Google Scholar 

  58. Takaki S, Sakaguchi H, Anai H, et al. Long-term outcome of transcatheter subsegmental and segmental arterial chemoemobolization using lipiodol for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2012;35:544–554.

    Article  PubMed  Google Scholar 

  59. Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255–264.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis. 2016;48:571–577.

    Article  CAS  PubMed  Google Scholar 

  61. Mantry PS, Mehta A, Madani B, et al. Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study. J Gastrointest Oncol. 2017;8:799–807.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Kim DY, Park BJ, Kim YH, et al. Radioembolization with Yttrium-90 resin microspheres in hepatocellular carcinoma: a multicenter prospective study. Am J Clin Oncol. 2015;38:495–501.

    Article  CAS  PubMed  Google Scholar 

  63. Kolligs FT, Bilbao JI, Jakobs T, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int.. 2015;35:1715–1721.

    Article  PubMed  Google Scholar 

  64. Gramenzi A, Pettinato C, Cappelli A, et al. Reply to: “Sorafenib or (90) Y loaded resin microsphere radioembolization for locally-advanced hepatocellular carcinoma, what should we trust?”. Liver Int. 2015;35:1780–1781.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Diagnostic and Interventional Radiology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany

    Thomas J. Vogl & Tatjana Gruber-Rouh

Authors
  1. Thomas J. Vogl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tatjana Gruber-Rouh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas J. Vogl.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vogl, T.J., Gruber-Rouh, T. HCC: Transarterial Therapies—What the Interventional Radiologist Can Offer. Dig Dis Sci 64, 959–967 (2019). https://doi.org/10.1007/s10620-019-05542-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-019-05542-5

Keywords

Search

Navigation